Psoas compartment block (PCB) is used for surgery and pain relief in patients undergoing hip or knee surgery. The block does not provide anaesthesia of sciatic nerve and additional sciatic nerve block is necessary in the case of surgery. In consequence, large doses of local anaesthetics (LA) are administered with potential riskof LA intoxication. Factors influencing systemic concentrations of LA are the amount of LA injected, the site of injection, and the addition of vasoconstrictive agents. 1 Only two studies investigated ropivacaine pharmacokinetics after PCB alone. 2 3 Both used epinephrine as vasoconstrictive and took venous samples for testing. Arterial plasma concentrations are known to be higher during the early phase of systemic absorption and therefore of more value regarding toxicity of LA. 4 5 Total knee replacement is a typical surgery in the elderly. Often, these patients present with cardiovascular comorbidity and epinephrine might have adverse effects. 1 Only one study investigated ropivacaine pharmacokinetics after PCB without the use of epinephrine. 6 PCB was combined with sciatic block and blood sampling was started thereafter. This design represents clinical practice but is not useful when only psoas compartment kinetics are investigated. Free plasma concentrations are responsible for LA toxicity, 1 but no study has investigated it so far in the setting of PCB. The aim of our study was to measure free and total plasma concentrations of ropivacaine after PCB. We were especially interested in the early phase of systemic absorption, analysed arterial samples, and omitted the use of vasoconstrictive additives.
Methods
The local Ethics Committee approved the study protocol (EK218122003) and written informed consent was obtained from all patients. 
PCB blocks
All blocks were performed in a holding area by one experienced anaesthetist (M.H.). Patients were placed in the lateral decubitus with the operative knee up. PCBs were performed according to Chayen's approach with the insertion point 3 cm below Tuffier's line (transverse line between the upper borders of iliac crests) and 5 cm laterally to the spinous process line. 7 After sterile preparation and draping, an LA skin wheal was raised using lidocaine 20 mg (AstraZeneca GmbH, Wedel, Germany). A 15 cm long insulated needle (Plexolong, Pajunk, Geisingen, Germany) was inserted perpendicularly to all cutaneous planes. The needle was connected to a nerve stimulator (Stimuplex w HSN 11, Braun, Melsungen, Germany) initially set at 1 mA, 1.0 ms, and 2 Hz. Needle position was judged as correct when quadriceps contractions and patellar motion were elicited with a stimulating current below 0.5 mA at 0.1 ms pulse width. After gentle aspiration to exclude vessel penetration, 30 ml of ropivacaine 0.5% (AstraZeneca, Wedel, Germany) was administered within 45 s. Subsequently, an indwelling 20 G end-hole catheter (Plexolong, Pajunk, Geisingen, Germany) with a metal guide wire was threaded 5 cm beyond the needle tip. The onset of sensory block of PCB was assessed bilaterally every 5 min at the medial, anterior, and lateral regions of the thigh until 30 min after ropivacaine administration. Motor block of femoral and obturator nerve was tested by inability of extension in the knee joint and adduction and flexion of the thigh in the hip joint. Haemodynamic data were collected during the whole study period. Complications such as vascular puncture, intoxication signs, and bilateral block were registered.
Plasma ropivacaine sampling
Baseline blood samples were obtained for measurements of a 1 -acid glycoprotein and albumin concentrations. After drawing and discarding 5 ml of blood, an additional 5 ml of arterial blood was collected for determination of drug concentrations at the following time points: 0 (end of injection), 0.5, 1, 2, 3, 5, 10, 20, and 30 min after injection of ropivacaine. Blood samples were stored at 48C and centrifuged. Plasma was frozen at 2188C and stored until analysis. Plasma concentrations of ropivacaine were determined by means of liquid chromatography-tandem mass spectrometric method. A detailed description of the exact methodology has been described elsewhere. 8 Protein precipitation was used to determine total plasma concentration of ropivacaine. Plasma concentrations of unbound ropivacaine were determined after ultrafiltration of the samples without prior protein precipitation.
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Statistics
Values are given as means with 25/75 percentiles and diagrammed in boxplots. The area under the plasma concentration-time curve (AUC) was calculated using the trapezoidal rule. The Pearson correlations were calculated to assess dependencies between protein concentrations and concentrations of total and unbound ropivacaine.
Results
Patient characteristic data of the patients are shown in Table 1 . Measurements of the different plasma proteins yielded decreased total protein values in four patients and decreased albumin value in one patient. Total and unbound plasma concentrations of ropivacaine are given in Table 2 . In Patient 11, maximum measured plasma concentration was measured at time point 0, suggesting that intravascular injection of ropivacaine occurred. The plasma concentrations in this patient declined with every further measurement and were 1686 ng ml 21 (total concentration) and 42 ng ml 21 (unbound concentration) at time point 30. The data of this patient were not included into the graphs but are part of the discussion. In nine of the remaining 10 patients, we measured the plasma concentration of ropivacaine at time point 0. The first drawn plasma probes yielded a mean total ropivacaine concentration of 165 (range 0-763) ng ml 21 . Thirty seconds later, all plasma samples contained measurable concentrations of ropivacaine. In most patients, maximum free and total plasma concentrations were measured 10 min after ropivacaine injections ( Table 2 ). The time course of the plasma concentrations are depicted in Figures 1 and 2 . The maximum measured plasma concentrations showed wide inter-individual range. Unbound fractions of ropivacaine were between 1% and 5%. The Pearson correlation between plasma concentrations of total and unbound ropivacaine was 0.96. All other correlations were very weak or negative.
No signs of LA toxicity or other complications were observed, also in the patient with the presumed partial intravascular injection. Cardiovascular parameters remained unchanged.
The loss of cold/warm discrimination in the medial, anterior, and lateral aspects of the thigh was achieved in all 11 patients after 30 min. Only one patient showed failed adductor motor block indicating incomplete obturator nerve block. No patient showed bilateral block or other symptoms indicating epidural spread of ropivacaine. 
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Hü bler et al. Table 3 Pharmacokinetic variables after lumbar injections of LA. *Data are means (standard deviation) (no range was given). Art, arterial; B, bupivacaine; C max , peak concentration; Epi, epinephrine; free, unbound concentration of LA; L, lidocaine; LA, local anaesthetic; LB, levobupivacaine; M, mepivacaine; M(S2), S(2)-mepivacaine; M(R+), R(+)-mepivacaine; R, ropivacaine; total, total concentration of local anaesthetic; T max , time to peak concentration; ven, venous 
Discussion
This study investigated arterial plasma concentrations of ropivacaine without the use of a vasoconstrictor after injection of this LA into the psoas compartment. Our main finding is that some fraction of ropivacaine is absorbed rapidly from the psoas compartment. Studies investigating LA pharmacokinetics after lumbar injections are sparse (Table 3) . They evaluated lidocaine, 10 mepivacaine, 11 12 bupivacaine, 13 14 levobupivacaine, 14 15 or ropivacaine. 2 3 6 14 The different designs of the studies make their direct comparison very difficult. The majority used epinephrine as additive, 2 3 10-14 but three studies did not. 6 13 15 The blood samples were either of arterial 11 -15 or of venous origin. 2 3 6 10 Only three studies looked at the plasma concentrations of the LA after sole injections into the psoas compartment, 2 3 13 the other studies performed at the same time also blocked the sciatic nerve 6 10-12 14 15 and started sampling after the second injections. The latter therefore lack a true time point zero for evaluating early systemic absorption kinetics from the psoas compartment. This is especially true because the time intervals between lumbar injections and first blood samples drawn were not always mentioned. Kaloul and colleagues 2 investigated ropivacaine pharmacokinetics after the LA was given as a bolus with epinephrine followed by a continuous infusion without epinephrine. Also, they started blood sampling not before 15 min after the injections. Gained information regarding early pharmacokinetics with special focus on maximum plasma concentrations is therefore very limited. The other study investigating ropivacaine pharmacokinetics started blood sampling 5 min after the injections. 3 In contrast to our study, they added epinephrine and measured venous plasma concentrations. Unfortunately, they only reported mean values with standard deviations for the times to maximum measured plasma concentrations, but their diagram showing ropivacaine concentrations vs time suggests that in some patients, maximum values must have occurred early. Our study focused especially on the very early time period after the injections. We choose to analyse arterial samples for two reasons: first, the drug concentrations revealed are more likely to reflect the concentrations in vital tissues. Secondly, peripheral venous sampling is more prone to variability and artifact due to local circulatory changes at the sampling site. A time period of 30 min appears to be necessary before an equilibrium between arterial and peripheral venous samples is established. 4 Additionally, it is known that in the early phase of systemic absorption arterial are higher than venous concentrations. 5 16 Ropivacaine almost instantaneously appeared in the plasma after having completed the injections. Altermatt and colleagues 15 reported in a letter to the editor early measured maximum plasma concentrations of levobupivacaine after combined posterior lumbar plexus and sciatic nerve block. They decided to stop the study and recommended epinephrine as additive. It is true that epinephrine slows the systemic absorption of LA, 5 One of our patients probably experienced partial intravascular administration of ropivacaine because maximum plasma concentration was measured at time point 0 and declined over time. Nevertheless, the neural block was successfully established and no signs of toxicity were observed. We believe that intravascular administration occurred at the start of injection and that the vessel was pushed aside and maybe even squeezed by the volume injected. The performed gentle aspiration was unable to detect the vessel penetration.
Circulating drug concentrations are often used as a convenient way of guessing the related tissue concentrations and predicting the responses. But only unbound LA is responsible for toxic side-effects, and therefore, total LA plasma concentrations do not give valid information for safe doses of LA. 1 17 Knudsen and colleagues 17 showed that there is a huge variability regarding individual toxic concentrations. They found lower limits of free serum ropivacaine concentrations between 340 and 850 ng ml 21 at which healthy volunteers started to report symptoms of central nervous system toxicity. In our patients, free plasma concentrations of ropivacaine were much lower and represented only 1-5% of the total plasma concentrations ( Table 2 ). Plasma binding of ropivacaine is known to be 94% (1%). 18 However, it is dependent on many variables such as pH and blood cell uptake. 19 Most cases of acute toxicity occur because of accidental intravascular injections. It appears that the speed of increase in LA concentrations in the plasma is one if not the major factor. 19 In our study, we injected the LA within 45 s. This injection speed eventually promoted the early detection of ropivacaine in the plasma. In summary, this is the first study that measured free and total arterial plasma concentrations of ropivacaine after lumbar injections with focus on the early phase of systemic absorption. No vasoconstrictor was added and maximum plasma concentrations occurred very early. Systemic absorption is inevitable, and therefore, we strongly recommend slow and fractionated injections and, if not contraindicated, adding epinephrine as vasoconstrictor.
